SESSION TITLE: Asthma Posters
SESSION TYPE: Poster Presentations
PRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PM
PURPOSE: Despite optimal treatment, some asthmatic remain symptomatic with frequent exacerbations and persistent obstruction of the airways. Tiotropium addition is associated with reduced risk of exacerbations and sustained bronchodilatation(BD). Objectives: Characterization of asthmatic patients with optimized treatment and treated with tiotropium. Assess the role of tiotropium in symptomatic control and lung function.
METHODS: Retrospective cohort study with asthmatic patients observed during 2012 and treated with tiotropium for at least 6 months. Data Collected: Demographic, anthropometric; Lung Function tests; co-morbidities and disease control.
RESULTS: 41 patients (32-78% women) which correspond to 10% of all patients followed. Mean age: 53,92 years(min:23;max:77) and mean BMI:30,31 Kg/m2 . 4(9,8%) are smokers, 19(46,1%) with rhinitis, 5(12,2%) sinusitis, 16(39%) GERD, 10(24,4%) depression and 19(46,3%) atopic. Inicial asthma severity: 1(2,4%) mild persistent; 16(39%) moderate persistent; 24(58,5%) severe persistent. Before triotropium: 16(39%) partly controlled; 25(61%) uncontrolled. After triotropium: 22(53,7%) controlled; 13(31,7%) partly controlled and 6(14,6%) uncontrolled. Before tiotropium the mean FEV1 preBD was 1,55L(61,76%) and postBD of 1,7 L(65,5%). After tiotropium mean FEV1 preBD was 1,64 L(68,65%) and postBD of 1,74 L(73,19%). There was an increase in FEV1 in the majority (68.3%, n = 28), with an average increase of 90 ml in preBD FEV1.
CONCLUSIONS: Most patients have co-morbidities and high BMI. In uncontrolled asthmatics despite optimal therapy, it was identified a better disease control and an increase in FEV1 with the addition of tiotropium.
CLINICAL IMPLICATIONS: Some asthmatic remain symptomatic with frequent exacerbations despite optimal treatment .Tiotropium addition may be an option in this patients.
DISCLOSURE: The following authors have nothing to disclose: Ana Gonçalves, Ricardo Lima, Ivone Pascoal, João Moura, Miguel Guimarães, Raquel Duarte, Aurora Carvalho
No Product/Research Disclosure Information